← Back to Search

Topoisomerase I inhibitors

Nitrocamptothecin for Pancreatic Cancer

Phase 3
Waitlist Available
Research Sponsored by Astex Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Karnofsky performance status 50-100%
Histologically or cytologically proven adenocarcinoma of the pancreas with failure or relapse after at least 1 prior chemotherapy regimen
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is comparing the effectiveness of nitrocamptothecin to other chemotherapy drugs for cancer of the pancreas.

Who is the study for?
This trial is for adults over 18 with recurrent or refractory pancreatic cancer who have tried at least one chemotherapy regimen. Participants must have adequate blood, liver, and kidney function and not be pregnant or nursing. They should not have had certain treatments recently and must agree to use contraception.Check my eligibility
What is being tested?
The study aims to compare the effectiveness of a chemotherapy drug called nitrocamptothecin against other chemotherapies in patients with pancreatic cancer that has come back or didn't respond to previous treatment. It's a phase III trial where patients are randomly assigned to different treatments.See study design
What are the potential side effects?
Chemotherapy drugs like nitrocamptothecin can cause side effects such as nausea, vomiting, hair loss, fatigue, decreased blood cell counts leading to increased infection risk, bleeding or anemia issues, and potential liver or kidney problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can perform most of my daily activities without assistance.
Select...
My pancreatic cancer has returned or worsened after at least one chemotherapy treatment.
Select...
I am over 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Astex Pharmaceuticals, Inc.Lead Sponsor
95 Previous Clinical Trials
7,961 Total Patients Enrolled
Lawrence A. Romel, MSStudy ChairAstex Pharmaceuticals, Inc.
2 Previous Clinical Trials

Media Library

Nitrocamptothecin (Topoisomerase I inhibitors) Clinical Trial Eligibility Overview. Trial Name: NCT00005870 — Phase 3
Pancreatic Cancer Research Study Groups:
Pancreatic Cancer Clinical Trial 2023: Nitrocamptothecin Highlights & Side Effects. Trial Name: NCT00005870 — Phase 3
Nitrocamptothecin (Topoisomerase I inhibitors) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005870 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this course of action been cleared by the FDA?

"Since this is a Phase 3 trial, there is both some efficacy data and multiple rounds of safety data, so the Power team rates the safety of this treatment as a 3."

Answered by AI

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What site did they apply to?
SuperGen, Incorporated
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
1999. "Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00005870.
All > Pancreatic Cancer
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top